silodosin / Generic mfg. - LARVOL DELTA

Medical Expulsive Therapy after Extracorporeal Shock Wave Lithotripsy: A Systematic Review and Network Meta-Analysis. (PubMed, Yonsei Med J) - "The tamsulosin-tadalafil combination represents the optimal pharmacological adjunct to ESWL. Our findings suggest that effective post-ESWL MET requires a broad therapeutic approach targeting multi-segmental ureteral relaxation and inflammation to clear fragment "showers," distinguishing it from the management of solitary ureteral stones."

Clinical • Journal • Retrospective data • Review • Inflammation • Renal Calculi

A Multicenter Randomized Cross-Over Study Evaluating the Efficacy and Safety of Silodosin in Adult Women With Voiding Dysfunction (clinicaltrials.gov) - P2 | N=150 | Not yet recruiting | Sponsor: Jaber Al Ahmad Al Sabah Hospital

New P2 trial

Alpha-Adrenoceptor Blockade as a Novel Pathway Toward Non-Hormonal Male Contraception: A Mechanistic and Clinical Evidence Review. (PubMed, J Clin Med) - "Agents such as tamsulosin and silodosin have been reported to induce anejaculation or markedly reduce semen volume, providing pharmacodynamic evidence of impaired seminal emission; however, these effects should not be considered equivalent to demonstrated contraceptive efficacy. α1-adrenoceptor antagonists represent a biologically plausible pharmacologic strategy for male non-hormonal contraception by interfering with seminal emission and sperm delivery without directly suppressing spermatogenesis. Further pharmacokinetic-pharmacodynamic studies and rigorously designed multicentre clinical trials are required to determine the optimal dosing strategy, completeness and consistency of seminal emission suppression, contraceptive effectiveness, safety, acceptability, and reversibility of this approach."

Clinical • Journal • Review • Cardiovascular • Sexual Disorders • ADRA1B

NQTIPS: The Efficacy and Safety of Silodosin in the Treatment of Benign Prostatic Hyperplasia (clinicaltrials.gov) - P4 | N=110 | Completed | Sponsor: Xintian Pharmaceutical | N=312 ➔ 110 | Recruiting ➔ Completed

Enrollment change • Trial completion • Benign Prostatic Hyperplasia

Pupil Size and Choroidal Thickness Changes With Tamsulosin vs. Silodosin in Benign Prostatic Hyperplasia Patients (clinicaltrials.gov) - P4 | N=40 | Not yet recruiting | Sponsor: Mohsen Pourazizi

New P4 trial • Benign Prostatic Hyperplasia • Ophthalmology

Iris Structural Changes With Tamsulosin vs. Silodosin in Benign Prostatic Hyperplasia Patients (clinicaltrials.gov) - P4 | N=40 | Not yet recruiting | Sponsor: Mohsen Pourazizi

New P4 trial • Benign Prostatic Hyperplasia

Novel eco-friendly spectrophotometric determination of potential combination silodosin and darifenacin hydrobromide in bulk and pharmaceutical formulations. (PubMed, BMC Chem) - "Recovery studies validated the accuracy of the methods in pharmaceutical formulations, with an average recovery of 100.37% for silodosin (direct method) and 100.96%, 99.87%, and 100.69% for darifenacin hydrobromide using fourier self-deconvolution, Ratio difference, and first derivative ratio methods, respectively. The procedures demonstrate a high level of environmental sustainability, as evidenced by Analytical GREEnness calculator (a comprehensive, flexible, and straightforward assessment approach that provides an easily interpretable and informative result for evaluating greenness), Modified Green Analytical Procedure Index (which merges the advantages of the visual impact of Green Analytical Procedure Index with the precise total score of the analytical Eco-Scale and provides an overall assessment of the method greenness by calculating a total score), spider chart, green solvents selection tool (spider chart and green solvent selection tools were applied to select..."

Journal • Benign Prostatic Hyperplasia • Overactive Bladder

Spectrofluorimetric Determination of Silodosin Using NBD-Cl Reagent: Applications to Capsules and Content Uniformity Testing. (PubMed, Luminescence) - "This approach is robust and avoiding costly instrumentation and chromatographic experiments. Its simplicity, reproducibility, and regulatory compliance make it promising for pharmacokinetic research, quality control, and clinical laboratories that need accurate SDN analysis in complicated matrices."

Journal • Benign Prostatic Hyperplasia • ADRA1B

Medical expulsive therapies for ureteric stones: an umbrella review of network meta-analyses with novel evidence grading. (PubMed, Int Urol Nephrol) - "Naftopidil plus corticosteroids was the most effective MET for stone expulsion based on evidence certainty assessment, followed by Silodosin. Clinical care and future research should take into account the ranking evidence collated in this umbrella review."

Journal • Review • Pain

Tamsulosin Dose Escalation or Silodosin Switch Before Trial Without Catheter in BPH-Related Acute Urinary Retention (clinicaltrials.gov) - P4 | N=378 | Recruiting | Sponsor: Beni-Suef University

New P4 trial • Benign Prostatic Hyperplasia

Silodosin for Urinary Symptoms in Female Patients With Multiple Sclerosis (clinicaltrials.gov) - P4 | N=60 | Recruiting | Sponsor: Atlantic Health System

New P4 trial • CNS Disorders • Multiple Sclerosis

High-Fat Diet Induces Urothelial and Detrusor Dysfunction via Adrenoreceptor and Muscarinic Receptor Pathways in a Murine Model (AUA 2026) - "These results indicate that HFD-induced urinary bladder dysfunction is linked to urothelial dysfunction, particularly involving adrenoreceptors and muscarinic acetylcholine receptors, which contribute to impaired detrusor contractility."

Preclinical • Genetic Disorders • Obesity • Urology

Comparative Safety Profiles of a1-Adrenergic Blockers in Men with LUTS: Insights from a FAERS Disproportionality Study (AUA 2026) - "After deduplication per FDA guidance, only male cases listing alfuzosin, doxazosin, tamsulosin, terazosin, or silodosin as the primary suspect drug were included. This large-scale FAERS analysis reveals distinct safety fingerprints within the α-blocker class. Highly selective agents (tamsulosin, silodosin) were characterised by strong ejaculatory and ocular signals, whereas less selective agents (terazosin, doxazosin) displayed prominent vasodilatory patterns. These findings complement clinical evidence and support individualised α-blocker selection based on patient comorbidities and treatment priorities."

Clinical • Hypotension • Ophthalmology

Intermittent Self-Catheterization in Male Patients with BOO and AUR Might Reintroduce Spontaneous Micturition Outcomes from a Prospective Study (AUA 2026) - "At emergency admission (T0), all patients were initially treated with IDC and started on silodosin 8 mg daily... CISC proved as effective as IDC in restoring spontaneous voiding in patients with de novo AUR secondary to BPH. CISC was associated with significantly better quality of life and overall patient satisfaction, despite higher urethral discomfort and a more complex management. These results support CISC as a feasible and patient-preferred alternative to IDC in the management of AUR due to BPH."

Clinical • Benign Prostatic Hyperplasia • Infectious Disease • Nephrology • Urology

Effect of Preoperative Silodosin on Outcomes of Ureteroscopy for Ureterolithiasis: A Systematic Review and Meta-Analysis (AUA 2026) - "Silodosin stands out among α-blockers for its superior efficacy and tolerability profile. Preoperative silodosin reduces ureteral injuries, operative time, and complications, supporting its use to improve safety and efficiency of URS for ureterolithiasis."

Retrospective data • Review • Renal Calculi

Effect of Adjuvant Silodosin on Stone Clearance After Extracorporeal Shock Wave Lithotripsy for Renal Stones: A Randomised Controlled Trial. (PubMed, J Clin Med) - "However, a possible benefit was observed in patients with renal stones measuring 10-20 mm, together with improved pain-related outcomes. These findings suggest that silodosin may have a role in selected patients, but the subgroup effects should be considered hypothesis-generating rather than definitive."

Journal • Nephrology • Pain • Renal Calculi

Real-world incidence of nausea and vomiting induced by antineoplastic agents: insights and future directions from the Japanese adverse drug event report database. (PubMed, Support Care Cancer) - "Although there is a trend toward improvement in NV management with increased adherence to antiemetic therapies, a substantial gap remains between guidelines and actual practice. The need for tailored management strategies based on the onset patterns of NV for specific agents has been emphasized. Investigating the mechanisms underlying the antiemetic effects of adjunctive therapies, such as silodosin and meropenem, may pave the way for new antiemetic options for oral antineoplastic agents."

Adverse events • Journal • Real-world evidence • Oncology

INTRAVASCULAR LARGE B-CELL LYMPHOMA DIAGNOSED BY RENAL BIOPSY PRESENTING WITH NEPHROTIC SYNDROME (ISN-WCN 2026) - "His past history included hypertension, dyslipidemia, and chronic obstructive pulmonary disease, treated with amlodipine, atorvastatin, indacaterol, and silodosin...R-CHOP chemotherapy (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone) was initiated, followed by high-dose methotrexate for CNS prophylaxis...This case emphasizes the importance of considering hematologic malignancy in the differential diagnosis of nephrotic syndrome with unexplained fever, even in the absence of hematologic abnormalities. Early renal biopsy allowed timely R-CHOP chemotherapy and resulted in favorable clinical and renal outcomes."

Biopsy • B Cell Lymphoma • Cardiovascular • Chronic Obstructive Pulmonary Disease • Diffuse Large B Cell Lymphoma • Dyslipidemia • Glomerulonephritis • Hematological Malignancies • Hypertension • Immunology • Large B Cell Lymphoma • Lymphoma • Metabolic Disorders • Nephrology • Non-Hodgkin’s Lymphoma • Pulmonary Disease • Renal Cell Carcinoma • Renal Disease • Respiratory Diseases • BCL6 • CD20 • IL2 • IRF4 • PTPRC

Evaluating the safety profile of α-1 blockers, 5α-reductase inhibitors, and PDE5I for BPH: a disproportionality analysis of real-world adverse events based on FDA adverse event reporting system (FAERS). (PubMed, Aging Male) - "Reports of adverse events (AEs) in male BPH patients receiving AUA guideline-recommended drugs including α-1 blockers (tamsulosin, silodosin, doxazosin, and alfuzosin), 5ARIs (finasteride and dutasteride), and tadalafil were extracted. Sixteen significant AEs were detected, including pollakiuria, gynecomastia, breast pain and so on, with distinct reporting patterns across drug classes. This large-scale pharmacovigilance analysis identified distinct post-marketing safety signals among guideline-recommended pharmacotherapies for BPH, confirming known risks and suggesting potential novel adverse-event signals warranting further investigation."

Adverse events • Journal • Real-world evidence • Retrospective data • Benign Prostatic Hyperplasia • Pain

Silodosin vs Tamsulosin for LUTS Due to BPH: A Randomized Crossover Trial (clinicaltrials.gov) - P4 | N=140 | Not yet recruiting | Sponsor: Ain Shams University

New P4 trial • Benign Prostatic Hyperplasia

Efficacy and safety of α1-adrenergic blockers after extracorporeal shock wave lithotripsy in pediatric kidney stones. (PubMed, Pediatr Surg Int) - "Adjunctive therapy with α1-blockers after ESWL in children with urolithiasis improves treatment efficacy, shortens stone expulsion time, reduces pain, and demonstrates a favorable safety profile. An optimal timeframe for efficacy assessment is 6 days post-ESWL."

Journal • Nephrology • Pain • Pediatrics • Renal Calculi • Urolithiasis

Molecular insights into Silodosin's anti-cancer effects: a promising repurposing strategy for breast cancer. (PubMed, Cell Death Discov) - "While its known α1A-AR antagonism may contribute to its effects, silodosin could also act as an ER ligand, modulating estrogen-driven pathways essential in breast cancer development. This study provides the first experimental and computational evidence supporting the repurposing of silodosin as a potential multi-targeted therapeutic agent for breast cancer, opening promising new opportunities for patients with limited treatment options and encouraging further preclinical and clinical studies."

Journal • Breast Cancer • Hormone Receptor Breast Cancer • Oncology • Solid Tumor • ER

Preparation of Two Process-Related Impurities of a Key Intermediate of Silodosin Under Baeyer-Villiger and Fenton Conditions. (PubMed, Molecules) - "Furthermore, by adding 20 mM FeCl3 into the above 10% hydrogen peroxide solution, IDI became the major product in a yield of ~43% under this Fenton reaction-like condition. The probable formation mechanism of IDI was discussed and validated in the context of certain structurally similar substrates."

Journal

Use of Alpha-Blockers Before RIRS: Assessment of Factors for Successful Ureteral Access Sheath Insertion. A Randomized Clinical Study (ChiCTR) - P=N/A | N=140 | Completed | Sponsor: St. Luke’s Clinical Hospital Russian Federation; St. Luke’s Clinical Hospital Russian Federation

New trial • Renal Calculi • Urolithiasis

Robot-assisted Reduction Pyeloplasty with 3D Image Navigation for Adult Giant Hydro-nephrosis: Technique and Clinical Outcomes. (PubMed, Int Braz J Urol) - "In studies with ≥10 days of preoperative use, silodosin significantly improved SFR (RR 1.17; 95% CI: 1.10-1.26; p < 0.00001). Preoperative silodosin reduces ureteral injuries, operative time, and complications, supporting its use to improve safety and efficiency of URS for ureterolithiasis."

Clinical • Clinical data • Journal • Review • Nephrology • Renal Calculi